JP2015524409A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524409A5 JP2015524409A5 JP2015523159A JP2015523159A JP2015524409A5 JP 2015524409 A5 JP2015524409 A5 JP 2015524409A5 JP 2015523159 A JP2015523159 A JP 2015523159A JP 2015523159 A JP2015523159 A JP 2015523159A JP 2015524409 A5 JP2015524409 A5 JP 2015524409A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- aryl
- heterocyclyl
- heteroaryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims description 232
- 125000001072 heteroaryl group Chemical group 0.000 claims description 226
- 125000003118 aryl group Chemical group 0.000 claims description 158
- 150000001875 compounds Chemical class 0.000 claims description 154
- 125000000217 alkyl group Chemical group 0.000 claims description 153
- 239000001257 hydrogen Substances 0.000 claims description 136
- 229910052739 hydrogen Inorganic materials 0.000 claims description 136
- 238000000034 method Methods 0.000 claims description 118
- 150000002431 hydrogen Chemical class 0.000 claims description 101
- 125000003107 substituted aryl group Chemical group 0.000 claims description 90
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 81
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 70
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 60
- 125000001475 halogen functional group Chemical group 0.000 claims description 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 35
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 35
- 239000001301 oxygen Substances 0.000 claims description 35
- 229910052760 oxygen Inorganic materials 0.000 claims description 35
- 229910052757 nitrogen Inorganic materials 0.000 claims description 27
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 27
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- YTWDBRIDKWWANA-UHFFFAOYSA-N methyl 4-hydroxy-7-phenoxyisoquinoline-3-carboxylate Chemical compound C1=CC2=C(O)C(C(=O)OC)=NC=C2C=C1OC1=CC=CC=C1 YTWDBRIDKWWANA-UHFFFAOYSA-N 0.000 claims description 4
- XPHVSEHSKXETDK-UHFFFAOYSA-N butyl 1-[(dimethylamino)methyl]-4-hydroxy-7-phenylsulfanylisoquinoline-3-carboxylate Chemical group C1=CC2=C(O)C(C(=O)OCCCC)=NC(CN(C)C)=C2C=C1SC1=CC=CC=C1 XPHVSEHSKXETDK-UHFFFAOYSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- WJGPMRFWBJZJOQ-UHFFFAOYSA-N methyl 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate Chemical group C1=CC2=C(O)C(C(=O)OC)=NC(C)=C2C=C1OC1=CC=CC=C1 WJGPMRFWBJZJOQ-UHFFFAOYSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000012298 atmosphere Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- -1 4-methoxyphenoxy Chemical group 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672191P | 2012-07-16 | 2012-07-16 | |
| US61/672,191 | 2012-07-16 | ||
| PCT/US2013/050538 WO2014014834A1 (en) | 2012-07-16 | 2013-07-15 | Process for making isoquinoline compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524409A JP2015524409A (ja) | 2015-08-24 |
| JP2015524409A5 true JP2015524409A5 (enExample) | 2016-09-01 |
| JP6196671B2 JP6196671B2 (ja) | 2017-09-13 |
Family
ID=48857024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015523159A Active JP6196671B2 (ja) | 2012-07-16 | 2013-07-15 | イソキノリン化合物を作製する方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9340511B2 (enExample) |
| EP (2) | EP3219706A1 (enExample) |
| JP (1) | JP6196671B2 (enExample) |
| KR (1) | KR102145272B1 (enExample) |
| CN (2) | CN103435546B (enExample) |
| AU (1) | AU2013290437B2 (enExample) |
| BR (1) | BR112015001106B1 (enExample) |
| CA (1) | CA2879238C (enExample) |
| CY (1) | CY2022018I2 (enExample) |
| DK (1) | DK2872487T3 (enExample) |
| ES (1) | ES2631655T3 (enExample) |
| HU (2) | HUE034409T2 (enExample) |
| IL (1) | IL236625B (enExample) |
| IN (1) | IN2015KN00265A (enExample) |
| MX (1) | MX350922B (enExample) |
| MY (1) | MY171483A (enExample) |
| NZ (1) | NZ704660A (enExample) |
| PL (1) | PL2872487T3 (enExample) |
| PT (1) | PT2872487T (enExample) |
| SG (1) | SG11201500234YA (enExample) |
| WO (1) | WO2014014834A1 (enExample) |
| ZA (1) | ZA201500664B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004031114D1 (de) | 2003-06-06 | 2011-03-03 | Fibrogen Inc | Stickstoffhaltige heteroarylverbindungen und deren verwendungen zur erhoehung des gehaltes von endogenem erythropoietin |
| CN105037323A (zh) | 2008-11-14 | 2015-11-11 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| CN103435546B (zh) | 2012-07-16 | 2016-08-10 | 菲布罗根有限公司 | 制备异喹啉化合物的方法 |
| BR112015001101A2 (pt) | 2012-07-16 | 2017-06-27 | Fibrogen Inc | formas cristalinas de um inibidor de prolil hidroxilase |
| KR20220164069A (ko) | 2013-06-06 | 2022-12-12 | 피브로겐, 인크. | Hif 하이드록실라제 억제자의 약학적 제형 |
| CN103694172A (zh) * | 2013-12-26 | 2014-04-02 | 辽宁亿灵科创生物医药科技有限公司 | 含氮杂芳基化合物的衍生物 |
| CA2959688C (en) | 2014-09-02 | 2024-02-27 | Sunshine Lake Pharma Co., Ltd. | Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin |
| WO2016045125A1 (en) * | 2014-09-28 | 2016-03-31 | Merck Sharp & Dohme Corp. | Inhibitors of hif prolyl hydroxylase |
| CN104447547B (zh) * | 2014-11-10 | 2017-04-19 | 苏州康润医药有限公司 | 4‑氨基异喹啉‑8‑甲酸甲酯的合成方法 |
| CN106146490B (zh) * | 2015-03-27 | 2018-10-23 | 沈阳三生制药有限责任公司 | 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途 |
| CN104892509B (zh) * | 2015-06-04 | 2018-03-09 | 苏州明锐医药科技有限公司 | 诺得司他的制备方法 |
| CN106187888A (zh) * | 2016-07-18 | 2016-12-07 | 江苏德源药业股份有限公司 | Fg‑4592单晶及其制备方法 |
| CN106478503A (zh) * | 2016-09-29 | 2017-03-08 | 上海勋和医药科技有限公司 | Roxadustat中间体的制备方法 |
| CZ2016627A3 (cs) | 2016-10-07 | 2018-04-18 | Zentiva, K.S. | Způsob přípravy (7-fenoxy-4-hydroxy-1-methylisochinolin-3-karbonyl)glycinu (roxadustatu) a jeho intermediátů založený na souběžném otevírání oxazolového kruhu, štěpení etheru a tvorbě iminu |
| CN107954931B (zh) * | 2016-10-17 | 2021-06-22 | 上海医药集团青岛国风药业股份有限公司 | 一种诺得司他的制备方法 |
| CN110225753B (zh) * | 2017-01-28 | 2022-12-09 | 金凯(辽宁)生命科技股份有限公司 | 用于制备5-苯氧基-1(3h)异苯并呋喃酮的方法 |
| CA3083672A1 (en) * | 2017-12-01 | 2019-06-06 | Dr. Reddy's Laboratories Limited | Process for the preparation of roxadustat and its intermediates |
| CN109956870A (zh) * | 2017-12-14 | 2019-07-02 | 南京卡文迪许生物工程技术有限公司 | 一种罗沙司他的合成方法及其中间体化合物 |
| CN110218184B (zh) * | 2018-03-01 | 2022-09-27 | 广东东阳光药业有限公司 | 诺德司他共晶及其制备方法 |
| CN110272386B (zh) * | 2018-03-16 | 2022-09-09 | 上海医药集团青岛国风药业股份有限公司 | 一种诺得司他的制备方法 |
| CN110526813B (zh) * | 2018-05-24 | 2022-06-28 | 杭州科巢生物科技有限公司 | 异喹啉化合物的制备方法及其中间体 |
| CN110028431B (zh) | 2018-06-05 | 2021-01-08 | 沈阳化工大学 | 一种三氟乙基硫醚（亚砜）取代苯类化合物及其用途 |
| CA3118752A1 (en) | 2018-11-09 | 2020-05-14 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| CN109776415B (zh) * | 2019-03-07 | 2020-11-17 | 福建南方制药股份有限公司 | 一种Roxadustat中间体的制备方法 |
| ES3014444T3 (en) | 2019-04-16 | 2025-04-22 | Vivace Therapeutics Inc | Bicyclic compounds |
| RU2709493C1 (ru) * | 2019-08-01 | 2019-12-18 | Марат Феликсович Фазылов | Способ получения роксадустата |
| US20220340532A1 (en) | 2019-08-07 | 2022-10-27 | Teva Pharmaceuticals International Gmbh | Processes for the preparation of roxadustat and intermediates thereof |
| CN112441975B (zh) * | 2019-09-03 | 2023-10-31 | 西藏嘉信景天药业有限公司 | 一种罗沙司他重要中间体的制备方法 |
| WO2021073623A1 (zh) * | 2019-10-18 | 2021-04-22 | 上海迪赛诺化学制药有限公司 | 一种制备异喹啉酮类化合物的方法 |
| CN112679431B (zh) * | 2019-10-18 | 2023-05-05 | 上海迪赛诺化学制药有限公司 | 一种制备异喹啉酮类化合物的方法 |
| CN112679430B (zh) * | 2019-10-18 | 2023-05-05 | 上海迪赛诺化学制药有限公司 | 一种制备异喹啉酮类化合物的方法 |
| CN113444042A (zh) * | 2020-03-27 | 2021-09-28 | 南京海润医药有限公司 | 一种罗沙司他的制备方法 |
| CN115867537A (zh) * | 2020-04-21 | 2023-03-28 | 迈兰实验室有限公司 | 改进的罗沙司他的制备方法 |
| CN111533691A (zh) * | 2020-06-08 | 2020-08-14 | 重庆三圣实业股份有限公司 | 一种罗沙司他的制备方法 |
| CN113801060B (zh) * | 2020-06-13 | 2025-06-27 | 苏州鹏旭医药科技有限公司 | 一种多取代异喹啉化合物的制备方法 |
| CN114539149A (zh) * | 2020-06-19 | 2022-05-27 | 济川(上海)医学科技有限公司 | 一种含异喹啉环的化合物、其制备方法及其应用 |
| CN112409258B (zh) * | 2020-11-20 | 2025-11-25 | 杭州科巢生物科技有限公司 | 一种罗沙司他的制备方法 |
| CN114644589A (zh) * | 2020-12-17 | 2022-06-21 | 鲁南制药集团股份有限公司 | 一种化合物n-[（4-羟基--1-甲基-3-异喹啉基）羰基]-甘氨酸的制备方法 |
| CN114671807A (zh) * | 2020-12-24 | 2022-06-28 | 联化科技（德州）有限公司 | 一种1-取代异喹啉类化合物的制备方法 |
| US20230101768A1 (en) * | 2021-08-13 | 2023-03-30 | The Board Of Regents Of The University Of Texas System | Method to treat manganese toxicity and manganese-induced parkinsonism in humans |
| CN116178260A (zh) * | 2021-11-26 | 2023-05-30 | 四川国康药业有限公司 | 一种治疗肾性贫血的化合物及其制备方法 |
| CN115124467A (zh) * | 2022-07-11 | 2022-09-30 | 天津力生制药股份有限公司 | 一种罗沙司他关键中间体的制备方法 |
| CN117105862A (zh) * | 2023-07-26 | 2023-11-24 | 北京福元医药股份有限公司 | 一种罗沙司他及其中间体的制备方法 |
| CN117486797A (zh) * | 2023-11-23 | 2024-02-02 | 传健生物医药(厦门)有限公司 | 一种罗沙司他关键中间体及罗沙司他的制备方法 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036964A (en) | 1973-10-11 | 1977-07-19 | Beecham Group Limited | Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis |
| US3989704A (en) | 1973-10-30 | 1976-11-02 | Sandoz, Inc. | 3-Substituted-4-aryl isoquinolines |
| DE2818423A1 (de) | 1978-04-27 | 1979-11-08 | Hoechst Ag | Neue isochinolinderivate und verfahren zu ihrer herstellung |
| DE3233424A1 (de) | 1982-09-09 | 1984-03-15 | Hoechst Ag, 6230 Frankfurt | Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| US4558006A (en) | 1983-02-04 | 1985-12-10 | Kirin-Amgen, Inc. | A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin |
| US4559403A (en) | 1983-05-19 | 1985-12-17 | Hoffmann-La Roche Inc. | Substituted isoquinolines |
| US4584379A (en) | 1985-01-22 | 1986-04-22 | Merrell Dow Pharmaceuticals Inc. | Isoquinoline thromboxane synthetase inhibitors |
| US4667016A (en) | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
| US4822800A (en) | 1986-06-09 | 1989-04-18 | Ortho Pharmaceutical Corporation | Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties |
| US4952588A (en) | 1987-11-27 | 1990-08-28 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides |
| US4966906A (en) | 1987-11-27 | 1990-10-30 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-isoquinolinecarboxamides |
| ES2101420T3 (es) | 1993-11-02 | 1997-07-01 | Hoechst Ag | Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. |
| EP0650961B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| CA2138929A1 (en) | 1993-12-30 | 1995-07-01 | Klaus Weidmann | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| WO1996018616A1 (en) | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| DK0944619T3 (da) | 1996-11-27 | 2007-02-05 | Bristol Myers Squibb Pharma Co | Hidtil ukendte integrinreceptorantagonister |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| FR2779963A1 (fr) | 1998-06-22 | 1999-12-24 | Centre Nat Rech Scient | Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer |
| IT1302677B1 (it) | 1998-10-15 | 2000-09-29 | Zambon Spa | Derivati benzazinici inibitori della fosfodiesterasi 4 |
| WO2000064877A1 (en) | 1999-04-26 | 2000-11-02 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
| IT1320162B1 (it) | 2000-02-09 | 2003-11-18 | Rotta Research Lab | Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico. |
| FI20002044A0 (fi) | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| US20040146964A1 (en) | 2001-03-21 | 2004-07-29 | Maxwell Patrick Henry | Assays, methods and means |
| GB0107901D0 (en) * | 2001-03-29 | 2001-05-23 | Cyclacel Ltd | Anti-cancer compounds |
| AU2002312371A1 (en) | 2001-06-13 | 2002-12-23 | Roland W. Burli | Aryl-benzimidazole compounds having antiinfective activity |
| US6777425B2 (en) | 2001-06-13 | 2004-08-17 | Genesoft Pharmaceuticals, Inc. | Isoquinoline compounds having antiinfective activity |
| US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
| WO2003053997A2 (en) | 2001-12-06 | 2003-07-03 | Fibrogen, Inc. | Methods of increasing endogenous erythropoietin (epo) |
| US8318703B2 (en) | 2001-12-06 | 2012-11-27 | Fibrogen, Inc. | Methods for improving kidney function |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| US20060251638A1 (en) | 2003-06-06 | 2006-11-09 | Volkmar Guenzler-Pukall | Cytoprotection through the use of hif hydroxylase inhibitors |
| DE602004031114D1 (de) | 2003-06-06 | 2011-03-03 | Fibrogen Inc | Stickstoffhaltige heteroarylverbindungen und deren verwendungen zur erhoehung des gehaltes von endogenem erythropoietin |
| US20060173046A1 (en) | 2003-07-15 | 2006-08-03 | Bell Ian M | Hydroxypyridine cgrp receptor antagonists |
| WO2005011696A1 (en) | 2003-08-01 | 2005-02-10 | Fibrogen, Inc. | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| CN1832920A (zh) | 2003-08-08 | 2006-09-13 | 特兰斯泰克制药公司 | 芳基和杂芳基化合物,组合物及其使用方法 |
| JP2008500834A (ja) | 2004-05-28 | 2008-01-17 | ファイブローゲン、インコーポレーテッド | Ｈｉｆプロリルヒドロキシラーゼ活性アッセイ |
| AP2007004047A0 (en) * | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
| ATE513833T1 (de) | 2005-03-02 | 2011-07-15 | Fibrogen Inc | Thienopyridinverbindungen und verfahren zu ihrer verwendung |
| US20060276477A1 (en) | 2005-06-06 | 2006-12-07 | Fibrogen, Inc. | Treatment method for anemia |
| JP5410751B2 (ja) | 2005-06-15 | 2014-02-05 | ファイブローゲン、インコーポレーテッド | がん治療のための化合物および方法 |
| US7831795B2 (en) * | 2005-11-28 | 2010-11-09 | Commvault Systems, Inc. | Systems and methods for classifying and transferring information in a storage network |
| CN101374815B (zh) | 2006-01-27 | 2013-07-17 | 菲布罗根有限公司 | 使低氧诱导因子（hif）稳定的氰基异喹啉化合物 |
| KR20080097446A (ko) | 2006-02-16 | 2008-11-05 | 피브로겐, 인크. | 뇌졸중의 치료를 위한 화합물과 방법 |
| KR101084635B1 (ko) | 2006-04-04 | 2011-11-18 | 피브로겐, 인크. | Ｈｉｆ 조절제로서 피롤로- 및 티아졸로-피리딘 화합물 |
| US7713986B2 (en) | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
| US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| WO2009100250A1 (en) | 2008-02-05 | 2009-08-13 | Fibrogen, Inc. | Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
| CN102264740B (zh) | 2008-08-20 | 2014-10-15 | 菲布罗根有限公司 | 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途 |
| CN105037323A (zh) | 2008-11-14 | 2015-11-11 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
| US20140171465A1 (en) | 2011-01-13 | 2014-06-19 | Fibrogen, Inc. | Methods For Increasing Reticulocyte Hemoglobin Content |
| US8921389B2 (en) | 2011-02-02 | 2014-12-30 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase |
| JP6099644B2 (ja) * | 2011-07-22 | 2017-03-22 | ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド | プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用 |
| JP6129217B2 (ja) | 2012-03-09 | 2017-05-17 | フィブロジェン インコーポレイテッド | Ｈｉｆヒドロキシラーゼインヒビターとしての４−ヒドロキシ−イソキノリン化合物 |
| CN103435546B (zh) | 2012-07-16 | 2016-08-10 | 菲布罗根有限公司 | 制备异喹啉化合物的方法 |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| BR112015001101A2 (pt) | 2012-07-16 | 2017-06-27 | Fibrogen Inc | formas cristalinas de um inibidor de prolil hidroxilase |
| RU2666144C2 (ru) | 2013-01-24 | 2018-09-06 | Фиброген, Инк. | Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты |
| KR20220164069A (ko) | 2013-06-06 | 2022-12-12 | 피브로겐, 인크. | Hif 하이드록실라제 억제자의 약학적 제형 |
-
2013
- 2013-07-15 CN CN201310302822.0A patent/CN103435546B/zh active Active
- 2013-07-15 BR BR112015001106-3A patent/BR112015001106B1/pt active IP Right Grant
- 2013-07-15 NZ NZ704660A patent/NZ704660A/en unknown
- 2013-07-15 HU HUE13740184A patent/HUE034409T2/en unknown
- 2013-07-15 KR KR1020157003197A patent/KR102145272B1/ko active Active
- 2013-07-15 MX MX2015000505A patent/MX350922B/es active IP Right Grant
- 2013-07-15 WO PCT/US2013/050538 patent/WO2014014834A1/en not_active Ceased
- 2013-07-15 MY MYPI2015000128A patent/MY171483A/en unknown
- 2013-07-15 DK DK13740184.0T patent/DK2872487T3/en active
- 2013-07-15 EP EP17155678.0A patent/EP3219706A1/en not_active Withdrawn
- 2013-07-15 JP JP2015523159A patent/JP6196671B2/ja active Active
- 2013-07-15 CA CA2879238A patent/CA2879238C/en active Active
- 2013-07-15 PL PL13740184T patent/PL2872487T3/pl unknown
- 2013-07-15 US US14/414,879 patent/US9340511B2/en active Active
- 2013-07-15 IN IN265KON2015 patent/IN2015KN00265A/en unknown
- 2013-07-15 ES ES13740184.0T patent/ES2631655T3/es active Active
- 2013-07-15 CN CN201610421229.1A patent/CN106083719B/zh active Active
- 2013-07-15 EP EP13740184.0A patent/EP2872487B1/en active Active
- 2013-07-15 AU AU2013290437A patent/AU2013290437B2/en active Active
- 2013-07-15 SG SG11201500234YA patent/SG11201500234YA/en unknown
- 2013-07-15 PT PT137401840T patent/PT2872487T/pt unknown
-
2015
- 2015-01-11 IL IL236625A patent/IL236625B/en active IP Right Grant
- 2015-01-29 ZA ZA2015/00664A patent/ZA201500664B/en unknown
-
2016
- 2016-03-17 US US15/073,251 patent/US9708269B2/en active Active
-
2022
- 2022-06-16 HU HUS2200030C patent/HUS2200030I1/hu unknown
- 2022-06-17 CY CY2022018C patent/CY2022018I2/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524409A5 (enExample) | ||
| RU2011116052A (ru) | Способ получения хинолоновых соединений область техники, к которой относится настоящее изобретение | |
| MX2014006992A (es) | Disales de acido malonico y metodo para preparar dihaluros de malonilo. | |
| AU2015221439B2 (en) | Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same | |
| RU2015106856A (ru) | Способ получения производных пиразолкарбоновой кислоты | |
| JP2012515142A5 (enExample) | ||
| JP2014511367A5 (enExample) | ||
| EA201170098A1 (ru) | Замещенные производные алкилпиримидин-4-она | |
| TW201035052A (en) | Process for manufacturing substituted 5-methoxymethylpyridine-2,3-dicarboxylic acid derivatives | |
| JP2012517965A5 (enExample) | ||
| CA2663044A1 (en) | Quinolone carboxylic acids, derivatives thereof, and methods of making and using same | |
| WO2014003203A3 (en) | Method for producing stereoselective epoxyketone compound | |
| JP2018508537A5 (enExample) | ||
| RU2016138800A (ru) | Новый способ получения производных триазина, пиримидина и пиридина | |
| RU2017131253A (ru) | Способы получения фторкетолидов | |
| JP6462703B2 (ja) | １−アルキル−３−ジフルオロメチル−５−フルオロ−１ｈ−ピラゾール−４−カルバルデヒド類及び１−アルキル−３−ジフルオロメチル−５−フルオロ−１ｈ−ピラゾール−４−カルボキシレート類を調製する方法 | |
| WO2008123349A1 (ja) | Ｎ－フェニル－ｎ’－フェニルスルホニルピペラジン誘導体の製造方法 | |
| EA200700064A1 (ru) | Способ получения эфиров 4,4-дифтор-3-оксобутановой кислоты | |
| JP2008519079A5 (enExample) | ||
| MX2013008595A (es) | Procedimiento mejorado para la preparacion de 2,2-difluoroetilamina. | |
| GEP20156350B (en) | New process for synthesis of ivabradine and their additional salts with pharmaceutically acceptable acid | |
| JP2010513515A (ja) | シリル試薬を用いたピペリドンからの不飽和ピペリジンの合成 | |
| RU2013138523A (ru) | Способ получения производного ароматического амида карбоновой кислоты | |
| JP2014525897A5 (enExample) | ||
| RU2014101998A (ru) | Производные пиперазина, способы их получения и их применение в лечении инсулинорезистентности |